Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine

Technology appraisal guidance
Reference number: TA535
Published: 08 August 2018

Evidence

Supporting evidence

Evaluation report
Committee papers (PDF 1.98 MB)

Published:

08 August 2018